22 May 2013
Keywords: Biogen Idec, Multiple sclerosis, DR6 antagonist, Remyelination
Article | 04 July 2011
US biotech firm Biogen Idec (Nasdaq: BIIB) has revealed results from a study that suggest that inhibiting death receptor-6 (DR6) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 July 2011
5 July 2011
21 May 2013
© 2013 thepharmaletter.com